84166 Federal Register / Vol. 89, No. 203 / Monday, October 21, 2024 / Notices 

Dated: October 16, 2024. 

Bruce A. George, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–24239 Filed 10–18–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Advisory Committee on 

Research on Women’s Health. 

The meeting will be open to the 

public as a virtual meeting. Individuals 

who plan to view the virtual meeting 

and need special assistance or other 

reasonable accommodations to view the 

meeting, should notify the Contact 

Person listed below in advance of the 

meeting. The meeting will be videocast 

and can be accessed from the NIH 

Videocasting and Podcasting website 

(https://videocast.nih.gov/). 

Name of Committee: Advisory Committee 

on Research on Women’s Health. 

Date: December 9, 2024. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: Briefing on the National 

Academies of Science, Engineering, and 

Medicine’s (NASEM) Assessment of NIH 

Research on Women’s Health. 

Place: National Institutes of Health, 9000 

Rockville Pike, Building 31, Bethesda, MD 

20892 (In-Person and Virtual Meeting). 

Contact Person: Vivian Ota Wang, Ph.D., 

FACMG, CGC, Deputy Director, Office on 

Research for Women’s Health, Division of 

Program Coordination, Planning and 

Strategic Initiatives, National Institutes of 

Health, 6707 Democracy Blvd., Bethesda, MD 

20892, 240–550–9892, otawangv@nih.gov. 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meetings. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

Information is also available on the 

Institute’s/Center’s home page: https://

orwh.od.nih.gov/, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: October 15, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–24238 Filed 10–18–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel; U01 

Cooperative Agreement for Clinical Trials in 

Hearing Disorders. 

Date: November 12, 2024. 

Time: 10:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Address: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Meeting Format: Virtual Meeting. 

Contact Person: Sonia Elena Nanescu, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, NIDCD, NIH, 6001 

Executive Blvd., Suite 8300, Bethesda, MD 

20892, (301) 496–8683, sonia.nanescu@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, HHS) 

Dated: October 15, 2024. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–24199 Filed 10–18–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Final Scientific Integrity Policy of the 

National Institutes of Health 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice of final policy. 

SUMMARY: The National Institutes of 

Health (NIH) is issuing this Final NIH 

Scientific Integrity Policy to promote a 

continuing culture of scientific integrity 

at NIH. This Policy codifies NIH’s longstanding expectations to preserve 

scientific integrity throughout all NIH 

activities, establishes key roles and 

responsibilities for those who will lead 

the agency’s scientific integrity program, 

and, as appropriate, establishes relevant 

reporting and evaluation mechanisms. 

DATES: This Final Policy is effective on 

December 30, 2024. 

FOR FURTHER INFORMATION CONTACT: 

Jessica Tucker, Ph.D., Acting Deputy 

Director, Office of Science Policy, NIH, 

at (301) 496–9838 or SciencePolicy@

od.nih.gov. 

SUPPLEMENTARY INFORMATION: 

Background 

Scientific integrity aims to make sure 

that science is conducted, managed, 

communicated, and used in ways that 

preserve its accuracy and objectivity 

and protect it from suppression, 

manipulation, and inappropriate 

influence (https://www.whitehouse.gov/ 

wp-content/uploads/2022/01/01-22- 

Protecting_the_Integrity_of_

Government_Science.pdf). In support of 

our mission, NIH has always sought to 

incorporate robust scientific integrity 

principles and practices throughout 

every level of its scientific enterprise. In 

fostering scientific integrity, NIH aims 

to ensure that (1) scientific findings are 

objective, credible, and readily available 

to the public, and (2) the development 

and implementation of policies and 

programs is transparent, accountable, 

and evidence-based. NIH has numerous 

policies and procedures to ensure the 

Nation’s investment in biomedical 


lotter on DSK11XQN23PROD with NOTICES1